Background. Most severe and fatal cases of pertussis occur in infants <8 weeks of age, before initiation of the primary pertussis vaccine series. Women are recommended to receive tetanus, diphtheria, and acellular pertussis (Tdap) vaccine at the start of the third trimester of each pregnancy to optimize transplacental transfer of antibodies to the fetus. This recommendation was made by the Advisory Committee for Immunization Practices based on immunogenicity data, and no studies in the United States have yet evaluated the effectiveness of this strategy in reducing pertussis incidence in infants.
Unvaccinated infants are at greatest risk of severe disease and death from pertussis and rely on passively acquired maternal antibodies for protection [1, 2] . All women in the United States are recommended to receive tetanus, diphtheria, and acellular pertussis (Tdap) vaccine between 27 and 36 weeks gestation during each pregnancy, regardless of prior Tdap history [3, 4] . Vaccination timing is critical to maximize antibody transfer to the infant [1, 5, 6] .
Recent observational studies indicate that infants whose mothers received Tdap during or after pregnancy had a reduced risk of pertussis in the United Kingdom [7] and Australia [8] . A casecontrol study in the United Kingdom also found that prenatal Tdap vaccine was 91% effective at preventing pertussis among infants <2 months of age [9] , but this study included only 10 case mothers and 39 control mothers who had received prenatal Tdap. These study findings suggest this strategy will protect many infants from pertussis in the first weeks of life, but more data are needed to fully demonstrate the effectiveness of prenatal Tdap vaccination, especially among infants in the United States.
We evaluated a cohort of women with documented Tdap doses in the California Immunization Registry (CAIR) to determine whether infants whose mothers received Tdap at 27-36 weeks gestation had a lower risk of pertussis in the first weeks of life than infants born to women who received postpartum Tdap.
METHODS
We evaluate the impact of Tdap receipt during pregnancy on the risk of pertussis in young infants using a retrospective cohort study. CAIR is a consortium of 10 regional immunization registries in California; 7 of the 10 account for 87% of California's population and are maintained by the California Department of Public Health (CDPH) Immunization Branch. Although participation in the registry is optional, many large health systems and pharmacy chains report doses to CAIR through direct entry or electronic exchange from health records, and birth record data from the California Vital Statistics is uploaded monthly into the CAIR registries. As of the first quarter of 2016, there were approximately 20.5 million patient records in the 7 CDPH-managed CAIR registries.
To construct the cohort, California birth certificate records from 2013 through 2014 were linked to CAIR records to identify women 14-44 years of age with a recorded Tdap administered during pregnancy or within 14 days post partum using a matching algorithm consisting of a combination of the following variables: name, date of birth, address and city of residence. The corresponding infants from this birth cohort were matched to CDPH pertussis surveillance data to identify infants <12 months of age reported with pertussis, using a matching algorithm consisting of a combination of the following variables: infant's name, sex, date of birth, city and county of residence, and mother and father's name.
Tdap was determined to occur during pregnancy if it was administered before the infant's date of birth and after the date of the last menses, as recorded on the birth certificate. The week of gestation for Tdap was calculated as the number of weeks between vaccination and the date of last menses or estimated by using the number of weeks from vaccination and the obstetric estimate of gestational age at the infant's birth. Tdap was considered postpartum vaccination if it was administered 0-14 days after the birth of the infant.
Mothers were considered vaccinated if Tdap was received between 27 and 36 weeks gestation during the pregnancy for the infected infant and unvaccinated if it was received 0-14 days post partum. Infants of women who received postpartum Tdap were used for the comparator group because their mothers were unlikely to have received Tdap during pregnancy. Infants whose mothers received Tdap during pregnancy but before 27 or after 36 weeks gestation were excluded from the primary analysis. A secondary analysis of prenatal Tdap was less restrictive; mothers were considered vaccinated if Tdap was received at any point during the pregnancy for the infected infant and unvaccinated if they received Tdap 0-14 days post partum.
The primary outcome of interest was pertussis in the infant <8 weeks of age, determined by presence of a case report of pertussis in the CDPH surveillance database. By California statute, laboratories and clinicians report suspected cases of pertussis to local public health departments, which complete case report forms containing demographic, clinical, laboratory, and epidemiologic data collected through patient and provider interviews and medical record reviews; all cases with an acute cough illness meeting the Council of State and Territorial Epidemiologists (CSTE) clinical case definition of pertussis or with laboratory detection of Bordetella pertussis by culture or polymerase chain reaction are subsequently reported to CDPH. Medical records are requested and reviewed by CDPH staff for hospitalized infants with pertussis to ensure accuracy of the surveillance data. A secondary outcome was pertussis in the infant occurring at ≤12 weeks of age.
Infants were considered non-case patients if they were reported with pertussis occurring at >12 weeks of age; pertussis infection in this age group may be attributable to missing diphtheria, tetanus, and acellular pertussis vaccine doses, and this information was not available for this cohort. Furthermore, infants with pertussis at >12 weeks of age have better outcomes, require fewer medical interventions, and have shorter hospitalization stays, if any.
Bivariate comparisons of characteristics between motherinfant pairs for prenatal versus postpartum Tdap were calculated using χ 2 tests for categorical variables, and associated relative risk (RRs) and 95% confidence intervals (CIs) were constructed. Two-sided P values were calculated using analysis of variance, the Wilcoxon-Mann-Whitney test and the Cochran-Armitage test to evaluate trends, as appropriate. Multivariate logistic regression was used to calculate the odds ratio (OR) and 95% CI for pertussis among infants whose mothers received prenatal Tdap versus postpartum Tdap, after controlling for potential confounders. Covariates found to be significant at the P < .05 level in the bivariate analysis were included in the multivariate models. Four models were constructed to evaluate the primary and secondary treatments and outcomes: Tdap at 27-36 weeks gestation and pertussis at age <8 weeks (model 1a) or ≤12 weeks (model 1b) and Tdap at any point during pregnancy and pertussis at age <8 weeks (model 2a) or ≤12 weeks (model 2b).
Vaccine effectiveness (VE) was calculated as (1 -OR) × 100% [10] . VE estimates, adjusted for race/ethnicity, number of prenatal visits, mother's country of birth, payer for prenatal care, number of prior births, infant sex, gestational age, and birth weight, were calculated for both end points of pertussis (<8 and ≤12 weeks of age).
Among women who received Tdap during pregnancy and ≥14 days before delivery of the infant, we also evaluated the timing of the Tdap dose. We used multivariate logistic regression to construct ORs and 95% CIs for the odds of pertussis among infants whose mothers received Tdap at 13-26 versus 27-36 weeks gestation as well as infants whose mothers received Tdap only during the third trimester, comparing 27-31 versus 32-36 weeks gestation, while controlling for preterm birth, number of prior live births, and age of the mother in all models.
RESULTS
A total of 74 791 women had a live birth during 2013 or 2014 in California and a recorded Tdap vaccine dose in CAIR administered during the pregnancy or within 14 days after delivery; 287 mother-infant pairs were excluded for having a gestational age <27 weeks or a birth weight of <500 g. Among the remaining 74 504 mothers, 42 941 (58%) were vaccinated during pregnancy and 31 563 (42%) post partum.
A total of 1562 infants reported to CDPH with pertussis within the first year of life were known to be born in California during 2013-2014 and have a gestational age ≥27 weeks and a birth weight ≥500 g; 562 (36%) were ≤12 weeks and 321 (21%) were <8 weeks of age. A total of 994 971 live births occurred in California during 2013-2014 with a gestational age ≥27 weeks and a birth weight ≥500 g. The overall incidence of pertussis among infants <12 months of age was 1.6 cases per 1000 births. Our cohort of 74 504 mother-infant pairs represented 7.5% of the total eligible birth cohort in California.
Differences were observed between the mother-infant pairs with prenatal Tdap compared with postpartum Tdap. Women vaccinated during pregnancy were more likely to be Hispanic, white, or black and less likely to be Asian/Pacific Islander (P < .001). Women vaccinated during pregnancy were also less likely to be born in the United States or covered by Medicaid and more likely to have had prior births (all P < .001). Infants born to women vaccinated during pregnancy were more likely to be female (P = .03) and less likely to be preterm or have low birth weight (P < .001) ( Table 1) .
In the cohort, 119 infants were reported with pertussis at <1 year of age, for an incidence of 1.6 cases per 1000 births. Of these, 35 (29%) were ≤12 and 25 (21%) were <8 weeks of age. Infants born to women who received prenatal Tdap were less likely to have pertussis at <8 or ≤12 weeks of age (both P = .01) but there was no difference in the risk of pertussis among all infants <1 year of age (P = .11) compared with infants born to women vaccinated post partum (Table 1) .
Among the 42 218 women vaccinated during pregnancy with known data, 77% received Tdap during the recommended window of 27-36 weeks gestation, 14% were vaccinated in the first or second trimester, and 9% received Tdap after 36 weeks gestation but before delivery (Table 2) . Infants whose mothers received Tdap vaccine at 27-36 weeks gestation were less likely to have pertussis at ≤12 weeks of age than infants whose mothers received Tdap during pregnancy but outside the window of 27-36 weeks (OR, 0.22; 95% CI, .08-.63). Among the 31 563 women vaccinated after delivery, most received Tdap within the first 2 days, suggesting that vaccine was received during hospital admission.
In the multivariate regression models, receipt of Tdap between 27 and 36 weeks gestation or at any point during pregnancy remained highly protective against infant pertussis at age <8 weeks (models 1a and 2a) and ≤12 weeks (models 1b and 2b) when other covariates were controlled for (Tables 3  and 4) . Race was dropped from the multivariate models to allow for convergence; all other covariates showed no association with pertussis except Hispanic ethnicity and the number of prior births, which were both significantly associated with an increased risk of pertussis at <8 and ≤12 weeks of age in all 4 models (Tables 3 and 4) .
The overall VE of Tdap vaccination at 27-36 weeks gestation was 85% (95% CI, 33%-98%) for preventing pertussis in infants <8 weeks of age and 72% (30%-89%) for preventing it in infants ≤12 weeks of age, compared with postpartum Tdap and with adjustment for maternal and infant covariates ( Table 5 ). The VE of Tdap at any point during the pregnancy was 64% (95% CI, 11%-85%) for preventing pertussis in infants <8 weeks of age and 53% (8%-76%) for preventing it in infants ≤12 weeks of age, compared with postpartum Tdap and with adjustment for maternal and infant covariates (Table 5 ). Unadjusted VE estimates were similar to adjusted, so only adjusted estimates were presented.
Among the 15 case patients ≤12 weeks of age whose mothers were vaccinated during pregnancy, only 6 (40%) were vaccinated at 27-36 weeks gestation. In the subanalysis of mother-infant pairs who received Tdap during pregnancy and ≥14 days before delivery, infants whose mothers were vaccinated during the second trimester were significantly more likely to have pertussis at age <8 weeks (OR, 8.1; 95% CI, 1.3-49.0) or ≤12 weeks (4.6; 1.39-15.25), when controlling for the age of the mother, number of prior births, and preterm birth (Table 6 ). Infants whose mothers received Tdap early in the third trimester (27-31 weeks gestation) had lower odds of pertussis at <8 or ≤12 weeks of age than infants whose mothers received Tdap vaccine at 32-36 weeks gestation, although CIs were wide and included the null value (Table 7) .
DISCUSSION
This is an important study demonstrating that prenatal Tdap vaccination prevents pertussis in young infants more effectively than postpartum Tdap vaccination. Importantly, our study also found that vaccination during the recommended window of 27-36 weeks gestation was more protective than vaccination received earlier in pregnancy. Although not significant, our findings also suggest that Tdap received earlier in the third trimester (27-31 weeks gestation) may be more effective than Tdap at >31 weeks gestation in reducing risk of pertussis among infants. Pertussis toxin (PT) promotes leukocytosis with lymphocytosis, leading to pulmonary hypertension and death in young infants with pertussis [11] ; antibodies to PT (anti-PT) prevent severe pertussis [12, 13] . Recently, the highest geometric mean concentrations for anti-PT were observed among infants whose Abbreviations: CI, confidence interval; Tdap, tetanus, diphtheria, and acellular pertussis; VE, vaccine effectiveness. a VE was adjusted for mother's ethnicity, number of prenatal visits, prior births, payer, mother's country of birth, infant's birth weight, and gestational age.
mothers were vaccinated at 26-33 weeks gestation [14] , suggesting that the optimal timing for antibody transfer and protection is early in the third trimester; however, more data are needed.
A strength of this study is that it compares 2 current vaccination strategies and clearly demonstrates that vaccinating women during pregnancy rather than post partum is the superior strategy to prevent infant pertussis. A limitation of the study is the lack of an unvaccinated comparison group. The VE estimates presented here are probably underestimates of the total impact of prenatal Tdap on pertussis in infants, because the comparison group is not unvaccinated mothers but rather mothers who received postpartum vaccination. Infants born to women who receive postpartum Tdap are thought to already have a lower risk of pertussis than those born to completely unvaccinated mothers [15, 16] . It is likely that prenatal Tdap is >86% effective at preventing pertussis in infants <8 week of age, compared with no Tdap vaccination.
The use of surveillance data to identify the outcome is another possible limitation but may be lessened owing to the high proportion of infant pertussis cases that are brought to medical care. In addition, routine surveillance activities include reviews of hospital discharge databases and mortality records to identify unreported cases. Infants with pertussis that was not diagnosed or treated in California would have been misclassified as noncases. Misclassification bias for the exposure is unlikely to be present in our study owing to use of provider-reported Tdap vaccination data from CAIR; these data were also collected before the outcome of pertussis in the infant, so any exposure misclassification would be nondifferential.
Significant differences were observed between mother-infant pairs with prenatal versus postpartum Tdap. This is expected given that vaccination during pregnancy may be a marker for both access and quality of prenatal care. Importantly, when placed in the multivariate model, these factors showed no association with risk of pertussis, except for prior births. Infants were 1.5 times more likely to have pertussis at <8 weeks of age with each prior birth of the mother, suggesting that older siblings increase the risk of pertussis, consistent with a recent study [17] .
Finally, our cohort may not be representative of all pregnant women in California. However, the incidence of pertussis among infants <12 months of age in our cohort was 1.6 cases per 1000 births, indistinguishable from the source population, suggesting that the cohort was representative with respect to risk of pertussis.
In conclusion, prenatal Tdap at 27-36 weeks gestation was 85% more effective at preventing pertussis in infants <8 weeks of age, compared with postpartum Tdap. Vaccination at 27-36 weeks gestation was more protective than vaccination before or after this window. Efforts should be made by prenatal care providers to provide Tdap to pregnant women on site during routine prenatal visits at the earliest opportunity between 27 and 36 weeks gestation. 
Notes

